The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
December 6th 2023
A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.
December 6th 2023
Dr Emily Sims reviews the study design of the clinical trials with teplizumab and shares key findings from the completed phase 2 trial.
Dr Emily Sims provides an overview of the stages of type 1 diabetes (T1D) and explains how teplizumab slows the immune-mediated destruction of beta cells.
Research from investigators in Ontario, Canada suggests the plateau in rates of cardiovascular disease and hospitalizations among people with type 2 diabetes seen in the last decade is masking a growing income-based disparity.
The January 2023 endocrinology month in review features coverage of the FDA’s approval of bexagliflozin, news surrounding semaglutide, and the introduction of an expert-led, diabetes-focused podcast to HCPLive Endocrinology.
With up to 40 years of follow-up, a retrospective study of matched pairs is providing an overview of the long-term risks and benefits of bariatric surgery in people with overweight or obesity.
A prospective, dual-center study of people with high-risk type 1 diabetes using multiple daily injections aged 13-25 years demonstrates the utility of this technology in this patient population.
Announced on January 23, the US FDA's approval of bexagliflozin (Brenzavvy) was awarded to TheracosBio and indicates the SGLT2 inhibitor for use as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The uptake of modern glucose-monitoring technologies for people with T1D and T2D may be dependent on out-of-pocket costs, suggesting the need to reconsider cost-benefit profiles of these devices.
Comparing MTO scanning against adrenal vein sampling, investigators in the UK found the noninvasive diagnostic option could improve the identification of primary aldosteronism and candidates for adrenalectomy.
An analysis of a commercial claims database offers insight into the increase in vision-threatening eye disease among people with diabetes aged younger than 65 years from 2009-2018, with results also detailing trends in anti-VEGF therapy during the same period.
In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Steven Russell, MD, PhD, the chief medical officer of Beta Bionics, for a discussion around his journey to becoming CMO as well as a deep dive into the iLet Bionic Pancreas and its potential in diabetes management.
A study examining associations between coffee metabolites and risk of NAFLD severity suggests people with type 2 diabetes had a lower risk of fibrosis and more severe NAFLD based on increased coffee consumption.
Announced by Novo Nordisk on January 12, the label update from the FDA removes a previous indication stating oral semaglutide (Rybelsus) should not be used as an initial therapy, which clears the way for the agent to be used as a first-line therapy in type 2 diabetes.
Using data from the SEARCH for Diabetes in Youth study, a new analysis suggests rates of type 1 diabetes in youth may increase by 65% between now and 2060, while rates of type 2 diabetes could increase more than 600% during that same period if left unchecked.
An analysis of data from type 1 diabetes prevention trials is shedding new light on factors associated with increased and decreased likelihood of screening for type 1 diabetes among participants considered eligible for each trial.
Eight studies provided evidence to suggest the relationship between diabetes and the onset of frozen shoulder, but more high-quality cohort studies may be necessary to better understand the nature of the relationship.
A patient in their mid-50s with a history of diabetes who had already been on antibiotics for 4 days for cellulitis diagnosed in your emergency department, but had not improved, and then, yesterday, noticed an ankle wound. What additional testing should be considered for this patient?
To commemorate the inaugural year and the success of Diabetes Dialogue in 2022, our editorial team has compiled a list of the 5 most popular episodes from the past year. Further in this article, we offer readers a look into each of our hosts top picks for episodes during 2022.